Modified Alpha-ketoamide Derivates as anti-Mpro inhibitors for Covid-19 treatment

Back to all technologies
Download as PDF
2021-GHOS-69205
Researchers at Purdue University have developed a new class of compounds that target the main protease (Mpro) in SARS-COV-2/Covid-19 infection.

With the world facing the coronavirus (Covid-19) pandemic, there is an immediate need for intensive protection from the severe acute respiratory illness associated with the disease. Currently, there is no effective pharmaceutical treatment available for SARS-COV-2 infection. These compounds developed by Purdue University researchers are newer modified versions of previous alpha-ketoamide derivatives that have shown potency as anti-viral agents against Covid-19. One of the compounds identified showed potent activity (IC50= 4.2micromolar) in SARS-COV-2 infected Vero-E6 cells.

Advantages:
-Excellent Antiviral Activity Against SARS-CoV-2 in Mammalian Cells
-Improved Drug-Like Properties

Potential Applications:
-Treatment of Covid-19
-Treatment of Coronavirus
-Pharmaceutical Research & Development

Technology Validation: The compounds have been validated in Vero-E6 cells.

Recent Publication:
"A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication"
Nature Communication
DOI: 10.1038/s41467-021-20900-6
Dec 1, 2020
Provisional-Gov. Funding
United States
(None)
(None)

(None)
PCT-Gov. Funding
WO
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org